Login to Your Account

NewCo News

Apofore Introducing New Diabetes Target ApoA-IV

By Jennifer Boggs
Managing Editor

Tuesday, September 4, 2012
The diabetes arsenal is chock full of marketed therapies – glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors and the so-called "glitazones" to name a few (though the latter has suffered from safety concerns over the past few years) – but the space has seen a shortage of promising new targets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription